Stephen R. Marder, MD

University of California, Los Angeles, California

  • 42Articles
  • 142.3KReads
  • 1996–2025Active
  • 141Collaborators
  • 2.2KCitations

About

Stephen R. Marder, MD, affiliated with the University of California, Los Angeles, has published extensively on schizophrenia and schizoaffective disorders, focusing on antipsychotic treatments, psychosocial interventions, and patient care. His work also covers cognition, mood disorders, addiction, and neurology, with contributions to clinical trial methodologies and treatment adherence. Marder's publications span from 1996 to 2025 and include analyses of specific medications such as risperidone, clozapine, and aripiprazole. He has frequently collaborated with researchers including John M. Kane and Nina R. Schooler.

Publications

JCP
Psychosocial Interventions and Functional Recovery in Schizophrenia
Academic Highlights

Psychosocial Interventions and Functional Recovery in Schizophrenia

December 17, 2025

A consensus panel of experts reviewed the evidence base for use of psychosocial interventions in schizophrenia and provides practical recommendations for optimizing functional recovery.
, , , et al
JCP
Original Research

Response to Subcutaneous Injectable Monthly Risperidone (RBP-7000): PANSS Item-Level Analysis

September 21, 2021

Phase 3 study data on the efficacy of RBP-7000 for schizophrenia were examined to see if dose-response relationships exist for different items of the Positive and Negative Syndrome Scale.
, , , et al
JCP
Consensus Statement

Consensus on Monitoring Blood Antipsychotic Levels

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
, , , et al
JCP
Article

Consensus Recommendations for Assessing Suicidal Ideation and Behavior

June 28, 2017

Industry experts gathered to develop guidance for standardized data collection and analysis of suicidal ideation and to guide the development of novel treatments in an effort to rectify the...
, , , et al
JCP
Original Research

Clozapine and Risperidone in Moderately Refractory Schizophrenia: A 6-Month Randomized Double-Blind Comparison

May 25, 2016

, , , et al
JCP
Educational Activity

Monitoring Treatment and Managing Adherence in Schizophrenia

October 15, 2013

JCP
Educational Activity

Clinician Perceptions, Expectations, and Management of Negative Symptoms in Schizophrenia

January 15, 2013

JCP
Original Research

Antipsychotic Medications & Schizophrenia

December 15, 2011

Explore an analysis on Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia.
, , , et al
JCP
Book Review

Medical Illness and Schizophrenia, 2nd ed

December 15, 2010

JCP
Original Research

Case Reports of Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment in Patients With Agitation

February 9, 2010

, , , et al
JCP
Original Research

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy

October 15, 2009

, , , et al
JCP
Book Review

Research Methods in Psychiatry, 3rd ed

January 15, 2009

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe